{"id":"748b079a6996","type":"article","url":"https://hartvaat.nl/2021/10/14/empagliflozine-en-renale-uitkomsten-bij-hartfalen-nejm-emperor-reduced-renal/","title":"Empagliflozine en renale uitkomsten bij hartfalen: NEJM EMPEROR-Reduced renal","title_en":"Empagliflozin and Major Renal Outcomes in Heart Failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["dapagliflozine","empagliflozine","emperor-trials"],"journal":"The New England journal of medicine","doi":"10.1056/NEJMc2112411","source_url":"https://doi.org/10.1056/NEJMc2112411","authors":["Milton Packer","Javed Butler","Faiez Zannad","Stuart J Pocock","Gerasimos Filippatos","João P Ferreira","Martina Brueckmann","Waheed Jamal","Cordula Zeller","Christoph Wanner","Stefan D Anker"],"significance":8,"published":"2021-10-14","source_date":"2021-10-14","image":"","kennis":["https://hartvaat.nl/kennis/farmacologie/sglt2-remmers-cardiovasculaire-trials/","https://hartvaat.nl/kennis/hartfalen/sglt2-remmers-bij-hartfalen/"],"congress":"","summary_en":"This EMPEROR-Reduced renal analysis showed that empagliflozin slowed the decline in eGFR and reduced the risk of serious kidney outcomes in patients with heart failure, demonstrating renoprotective effects of SGLT2 inhibition in the heart failure population.","created":"2026-07-03T10:29:27Z","updated":"2026-07-03T13:28:34Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"NEJM EMPEROR-Reduced renale analyse die het nierprotectieve effect van empagliflozine bij HF kwantificeerde.","abstract_original":""}